B Group Inc. Cuts Holdings in Apogee Therapeutics Inc. $APGE

Posted by Brian Himes on Jun 17th, 2026

B Group Inc. lessened its stake in Apogee Therapeutics Inc. (NASDAQ:APGE – Free Report) by 42.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,000 shares of the company’s stock after selling 15,000 shares during the period. Apogee Therapeutics makes up about 1.1% of B Group Inc.’s holdings, making the stock its 15th biggest holding. B Group Inc.’s holdings in Apogee Therapeutics were worth $1,510,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Commonwealth Equity Services LLC grew its stake in Apogee Therapeutics by 2.2% in the 4th quarter. Commonwealth Equity Services LLC now owns 7,151 shares of the company’s stock worth $540,000 after buying an additional 152 shares in the last quarter. Stifel Financial Corp grew its stake in Apogee Therapeutics by 3.5% in the 4th quarter. Stifel Financial Corp now owns 5,214 shares of the company’s stock worth $394,000 after buying an additional 175 shares in the last quarter. ANTIPODES PARTNERS Ltd grew its stake in Apogee Therapeutics by 41.2% in the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company’s stock worth $33,000 after buying an additional 246 shares in the last quarter. Comerica Bank grew its stake in Apogee Therapeutics by 1.0% in the 4th quarter. Comerica Bank now owns 35,872 shares of the company’s stock worth $2,708,000 after buying an additional 338 shares in the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in Apogee Therapeutics in the 4th quarter worth approximately $37,000. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Analyst Upgrades and Downgrades

APGE has been the subject of a number of research reports. Guggenheim boosted their price target on shares of Apogee Therapeutics from $130.00 to $160.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Truist Financial cut their price target on shares of Apogee Therapeutics from $83.00 to $81.00 and set a “hold” rating for the company in a research note on Wednesday, May 27th. Canaccord Genuity Group boosted their price objective on shares of Apogee Therapeutics from $89.00 to $130.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. Citigroup boosted their price objective on shares of Apogee Therapeutics from $95.00 to $125.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. Finally, Royal Bank Of Canada boosted their price objective on shares of Apogee Therapeutics from $82.00 to $97.00 and gave the stock a “sector perform” rating in a report on Monday, June 8th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $114.56.

View Our Latest Stock Analysis on APGE

Insiders Place Their Bets

In other Apogee Therapeutics news, insider Carl Dambkowski sold 5,500 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $78.71, for a total value of $432,905.00. Following the sale, the insider owned 205,648 shares of the company’s stock, valued at $16,186,554.08. This trade represents a 2.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael Thomas Henderson sold 20,000 shares of the firm’s stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $83.38, for a total transaction of $1,667,600.00. Following the completion of the sale, the chief executive officer directly owned 1,095,987 shares in the company, valued at approximately $91,383,396.06. This trade represents a 1.79% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 76,500 shares of company stock worth $6,323,295. Insiders own 24.30% of the company’s stock.

Apogee Therapeutics Stock Performance

Shares of APGE opened at $85.24 on Wednesday. The firm has a 50 day moving average price of $84.52 and a 200-day moving average price of $77.61. Apogee Therapeutics Inc. has a fifty-two week low of $34.34 and a fifty-two week high of $95.32. The firm has a market cap of $5.28 billion, a price-to-earnings ratio of -19.69 and a beta of 0.62.

Apogee Therapeutics (NASDAQ:APGE – Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The company reported ($1.06) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.01. As a group, equities research analysts predict that Apogee Therapeutics Inc. will post -4.45 earnings per share for the current year.

Apogee Therapeutics Company Profile

(Free Report)

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.